FDA label 39f5f856-b6e2-4aa3-bcdb-2cc97d2f948d

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
1ae6e28d-7133-4c36-c949-4fdc82f210e9
SPL ID
39f5f856-b6e2-4aa3-bcdb-2cc97d2f948d
Version
14
Effective date
2020-08-05
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:24

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, may occur. Should symptoms occur, discontinue ALPROLIX and administer appropriate treatment. ( 5.1 ) Development of neutralizing antibodies (inhibitors) to ALPROLIX may occur. Perform an assay that measures Factor IX inhibitor concentration if plasma Factor IX level fails to increase as expected or if bleeding is not controlled with an appropriate dose. ( 5.2 , 5.4 ) The use of Factor IX products has been associated with the development of thromboembolic complications. ( 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions have been reported with ALPROLIX. Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with Factor IX replacement products. The presence of inhibitors has been associated with allergic reactions with Factor IX replacement therapies, including with ALPROLIX. Evaluate patients experiencing allergic reactions for the presence of an inhibitor. Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. Discontinue use of ALPROLIX if hypersensitivity symptoms occur, and initiate appropriate treatment. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to Factor IX has been reported following administration of ALPROLIX, including in previously untreated patients. Monitor all patients regularly for the development of inhibitors by appropriate clinical observations and laboratory tests [ see Warnings and Precautions ( 5.4 )]. Evaluate patients experiencing allergic reactions for the presence of an inhibitor. Closely observe patients for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of exposure to the product. Individuals with Factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with ALPROLIX. 5.3 Thromboembolic Complications The use of Factor IX products has been associated with the development of thromboembolic complications, especially in individuals receiving continuous infusion through a central venous catheter. ALPROLIX should be administered as bolus infusion over several minutes [ see Dosage and Administration ( 2.3 )]. The safety of ALPROLIX administration by continuous infusion has not been studied. 5.4 Monitoring Laboratory Tests To confirm adequate Factor IX levels have been achieved and maintained, monitor plasma Factor IX activity by performing the one-stage clotting assay [ see Dosage and Administration ( 2.1 )]. Factor IX results can be affected by the type of aPTT reagent used. Measurement with a one-stage clotting assay using a kaolin-based aPTT reagent will likely result in an underestimation of activity level. Monitor for the development of Factor IX inhibitors if the expected Factor IX activity levels in plasma are not attained, or if bleeding is not controlled with the recommended dose of ALPROLIX. Perform a Bethesda assay to determine if Factor IX inhibitors are present.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Common adverse reactions (incidence ≥1%) reported in clinical trials were headache and oral paresthesia. Common adverse reactions (incidence ≥1%) from clinical trials were headache and oral paresthesia. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Biogen Inc. at 1-855-692-5776 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. In the multi-center, prospective, open-label clinical trial with ALPROLIX, 123 previously treated patients (PTPs, exposed to a Factor IX containing product for ≥100 exposure days) were evaluated, with 115 subjects treated for at least 26 weeks and 56 subjects treated for at least 52 weeks. Adverse reactions (ARs) were reported in 10 of 119 (8.4%) subjects treated with routine prophylaxis or episodic (on-demand) therapy. They are summarized in Table 3 . No subject was withdrawn from the trial due to an adverse reaction. In the trial, no inhibitors were detected and no events of anaphylaxis were reported. Table 3: Summary of Adverse Reactions *119 previously treated patients (PTPs) on routine prophylaxis or episodic (on-demand) therapy System Organ Class Adverse Reactions (AR) Number of Subjects (%) N=119* Nervous system disorders Headache Dizziness Dysgeusia 2 (1.7) 1 (0.8) 1 (0.8) Gastrointestinal disorders Paresthesia oral Breath odor 2 (1.7) 1 (0.8) General disorders and administration site conditions Fatigue Infusion site pain 1 (0.8) 1 (0.8) Cardiac disorders Palpitations 1 (0.8) Renal and urinary disorders Obstructive uropathy 1 (0.8) Vascular disorders Hypotension 1 (0.8) Obstructive uropathy was reported in one subject with hematuria who developed an obstructing clot in the urinary collecting system. The event resolved with hydration and the subject continued prophylactic treatment with ALPROLIX. A causal relationship of clot formation to ALPROLIX was not established. Immunogenicity Previously-treated patients participating in clinical trials were monitored for neutralizing antibodies to Factor IX. No subjects developed neutralizing antibodies to Factor IX. The detection of antibodies that are reactive to Factor IX is highly dependent on many factors, including the sensitivity and specificity of the assay, sample handling, timing of sample collection, concomitant medications and underlying disease. 6.2 Postmarketing Experience The following adverse reaction has been identified during the post-approval use of ALPROLIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: Factor IX inhibitor development Immune system disorders: hypersensitivity

adverse reactions table

<table ID="t3" width="100%"><caption>Table 3: Summary of Adverse Reactions </caption><col width="50.133%" align="left"/><col width="25.200%" align="left"/><col width="24.667%" align="left"/><tfoot><tr><td colspan="3" align="left" valign="top"><paragraph styleCode="footnote">*119 previously treated patients (PTPs) on routine prophylaxis or episodic (on-demand) therapy </paragraph></td></tr></tfoot><tbody><tr><td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold">System Organ Class</content></td><td align="left" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">Adverse Reactions (AR)</content></td><td align="left" valign="top" styleCode="Toprule Botrule Rrule"><content styleCode="bold">Number of Subjects (%)</content> <content styleCode="bold">N=119*</content></td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Nervous system disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Headache Dizziness Dysgeusia </td><td align="left" valign="top" styleCode="Botrule Rrule">2 (1.7) 1 (0.8) 1 (0.8) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Gastrointestinal disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Paresthesia oral Breath odor </td><td align="left" valign="top" styleCode="Botrule Rrule">2 (1.7) 1 (0.8) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">General disorders and administration site conditions</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Fatigue Infusion site pain </td><td align="left" valign="top" styleCode="Botrule Rrule">1 (0.8) 1 (0.8) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Cardiac disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Palpitations </td><td align="left" valign="top" styleCode="Botrule Rrule">1 (0.8) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Renal and urinary disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Obstructive uropathy </td><td align="left" valign="top" styleCode="Botrule Rrule">1 (0.8) </td></tr><tr><td align="left" valign="top" styleCode="Botrule Lrule Rrule"><content styleCode="bold">Vascular disorders</content></td><td align="left" valign="top" styleCode="Botrule Rrule">Hypotension </td><td align="left" valign="top" styleCode="Botrule Rrule">1 (0.8) </td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.